Page last updated: 2024-11-03

riluzole and Spinal Muscular Atrophies of Childhood

riluzole has been researched along with Spinal Muscular Atrophies of Childhood in 3 studies

Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.

Spinal Muscular Atrophies of Childhood: A group of recessive inherited diseases that feature progressive muscular atrophy and hypotonia. They are classified as type I (Werdnig-Hoffman disease), type II (intermediate form), and type III (Kugelberg-Welander disease). Type I is fatal in infancy, type II has a late infantile onset and is associated with survival into the second or third decade. Type III has its onset in childhood, and is slowly progressive. (J Med Genet 1996 Apr:33(4):281-3)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bosboom, W1
Vrancken, AF3
van den Berg, LH3
Wokke, J1
Iannaccone, ST3
Wadman, RI2
Bosboom, WM2
Wokke, JH2
van der Pol, WL1

Reviews

3 reviews available for riluzole and Spinal Muscular Atrophies of Childhood

ArticleYear
Drug treatment for spinal muscular atrophy type I.
    The Cochrane database of systematic reviews, 2009, Jan-21, Issue:1

    Topics: Child, Preschool; Humans; Infant; Neuroprotective Agents; Randomized Controlled Trials as Topic; Ril

2009
Drug treatment for spinal muscular atrophy type I.
    The Cochrane database of systematic reviews, 2011, Dec-07, Issue:12

    Topics: Child, Preschool; Humans; Infant; Neuroprotective Agents; Randomized Controlled Trials as Topic; Ril

2011
Drug treatment for spinal muscular atrophy type I.
    The Cochrane database of systematic reviews, 2012, Apr-18, Issue:4

    Topics: Child, Preschool; Disease Progression; Humans; Infant; Neuroprotective Agents; Randomized Controlled

2012